Psoriasis

Select from the various topics below and click on the link to get an inside view of how our P&T committee responded to the issue. 

Moderate to Sever Psoriasis and Biologics

Remicade Antibodies

Amevive Clinically Inferior

Remicade Third-Line

Stelara Replaces Enbrel

Humira Preference Over Stelara

First-line Biologics

Rebates Based on Drug Not Disease State

Enbrel Contract Loophole

Cost Per PASI-75 Response

Manage Formulary by Diagnosis

 

* PTP video clips play in windows media player.  To download click here, Mac users click here. 
 

 

top of page